A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants
Recommended Citation
Rodriguez NA, Moya F, Ladino J, et al. A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants [published correction appears in J Perinatol. 2023 Jan 16;:]. J Perinatol. 2023;43(5):601-607. doi:10.1038/s41372-022-01589-x
Abstract
Objective: To determine if oropharyngeal therapy with mother's own milk (OPT-MOM) reduces late-onset sepsis (L-OS; primary outcome), NEC, death, length of stay, time to full enteral nutrition (FEN) and full oral feeds in preterm infants (BW < 1250 g).
Design: Infants (N = 220) were randomized to Group A (milk) or B (placebo) and received 0.2 mL every 2 h for 48 h, then every 3 h until 32 weeks CGA.
Results: There were no significant differences in L-OS, NEC or death. Group A trended towards an 8-day reduction in stay, 8-day reduction in time to FEN and a 6-day reduction in time to full oral feeds, compared to B. While clinically relevant, due to large variability in outcomes and lack of power, p values were > 0.05.
Conclusion: OPT-MOM did not reduce L-OS, NEC or death. Group A trended towards a reduced stay and better nutritional outcomes, but results were not statistically significant.
Clinicaltrials: GOV: NCT02116699 .
Erratum in
- Correction to: A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants. Rodriguez NA, Moya F, Ladino J, et al. Correction to: A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants. J Perinatol. 2023;43(8):1084. doi:10.1038/s41372-023-01607-6
Document Type
Article
PubMed ID
36596945
Affiliations
Advocate Children's Hospital-Park Ridge